Re-activated T-cells for adoptive immunotherapy
OwnerMicheal L. Gruenberg, Surendra Chavaninventors
Life of this patent
Estimating the term…
Abstract
A method for increasing the cytokine production of T-cells intended for use in adoptive immunotherapy is provided. The method improves adoptive immunotherapy methods where the efficacy of the treatment is dependent, at least in part, on the amount of cytokine production from the cells. In practicing the method, ex-vivo produced T-cells intended for use in adoptive immunotherapy treatment protocols are allowed to rest after harvest and then are re-activated just prior to infusion.
Claims47
A method, comprising:
- re-activating harvested previously activated or primed T-cells, wherein the T-cells are cells for adoptive immunotherapy;
- and
- infusing them into a subject.
A composition of T-cells, comprising T-cells suspended in plasma, wherein the plasma is autologous with respect to the T-cells.
A composition of T-cells, comprising T-cells;
- and
- anti-CD3 and anti-CD28 mAb-conjugated colloidal size particles.
A method for extending the shelf-life of T-cells for adoptive immunotherapy, comprising suspending the T-cells in autologous plasma.
A composition, comprising activated T-cells and autologous peripheral blood monocytes (PBMC).
Dependencies are inferred from the claim text.